| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Histocompatibility Antigens Class I | 40 | 2024 | 64 | 6.730 |
Why?
|
| Peptides | 26 | 2023 | 280 | 3.690 |
Why?
|
| HLA-B Antigens | 22 | 2021 | 29 | 3.240 |
Why?
|
| Epitopes, T-Lymphocyte | 19 | 2022 | 45 | 3.180 |
Why?
|
| Antigen Presentation | 25 | 2024 | 78 | 2.980 |
Why?
|
| HLA-A Antigens | 20 | 2016 | 24 | 2.550 |
Why?
|
| CD8-Positive T-Lymphocytes | 19 | 2022 | 91 | 2.000 |
Why?
|
| Epitopes | 9 | 2018 | 171 | 1.860 |
Why?
|
| Peptide Fragments | 14 | 2017 | 197 | 1.660 |
Why?
|
| HLA Antigens | 16 | 2019 | 57 | 1.580 |
Why?
|
| West Nile virus | 6 | 2016 | 20 | 1.550 |
Why?
|
| Alleles | 21 | 2017 | 347 | 1.280 |
Why?
|
| HLA-A2 Antigen | 12 | 2015 | 17 | 1.220 |
Why?
|
| Receptors, Antigen, T-Cell | 7 | 2016 | 74 | 1.130 |
Why?
|
| Antibodies, Monoclonal | 7 | 2016 | 316 | 1.120 |
Why?
|
| Antigens, Neoplasm | 6 | 2022 | 50 | 1.090 |
Why?
|
| Amino Acid Sequence | 29 | 2019 | 674 | 1.070 |
Why?
|
| Genes, MHC Class I | 10 | 2016 | 12 | 1.040 |
Why?
|
| T-Lymphocytes | 10 | 2019 | 274 | 1.030 |
Why?
|
| Humans | 90 | 2023 | 26821 | 0.970 |
Why?
|
| Neoplasms | 7 | 2022 | 748 | 0.970 |
Why?
|
| Epitope Mapping | 3 | 2018 | 38 | 0.920 |
Why?
|
| Mass Spectrometry | 15 | 2022 | 186 | 0.920 |
Why?
|
| Protein Binding | 22 | 2022 | 631 | 0.900 |
Why?
|
| Immunodominant Epitopes | 6 | 2016 | 13 | 0.880 |
Why?
|
| Ligands | 18 | 2024 | 168 | 0.860 |
Why?
|
| West Nile Fever | 4 | 2013 | 15 | 0.850 |
Why?
|
| Viral Proteins | 5 | 2017 | 62 | 0.810 |
Why?
|
| Breast Neoplasms | 4 | 2019 | 441 | 0.790 |
Why?
|
| HIV-1 | 7 | 2014 | 54 | 0.780 |
Why?
|
| Molecular Sequence Data | 24 | 2014 | 1036 | 0.770 |
Why?
|
| Histocompatibility Antigens | 3 | 2018 | 8 | 0.750 |
Why?
|
| CD4-Positive T-Lymphocytes | 5 | 2019 | 100 | 0.730 |
Why?
|
| HLA-C Antigens | 8 | 2017 | 13 | 0.720 |
Why?
|
| Animals | 36 | 2022 | 9957 | 0.700 |
Why?
|
| Antibody Specificity | 6 | 2016 | 113 | 0.700 |
Why?
|
| Macrophage Migration-Inhibitory Factors | 3 | 2015 | 8 | 0.700 |
Why?
|
| Autoantigens | 5 | 2015 | 212 | 0.680 |
Why?
|
| Immunotherapy | 4 | 2022 | 135 | 0.660 |
Why?
|
| Cell Line, Tumor | 11 | 2022 | 1263 | 0.660 |
Why?
|
| Influenza A virus | 2 | 2010 | 29 | 0.660 |
Why?
|
| Proteome | 5 | 2018 | 75 | 0.640 |
Why?
|
| Cell Line | 14 | 2022 | 672 | 0.630 |
Why?
|
| Mice | 17 | 2022 | 4406 | 0.610 |
Why?
|
| Intramolecular Oxidoreductases | 2 | 2015 | 8 | 0.600 |
Why?
|
| Software | 1 | 2018 | 121 | 0.560 |
Why?
|
| Computational Biology | 1 | 2018 | 150 | 0.550 |
Why?
|
| Immunoglobulins | 3 | 2013 | 33 | 0.530 |
Why?
|
| Histocompatibility Testing | 9 | 2019 | 14 | 0.520 |
Why?
|
| Toxoplasma | 1 | 2016 | 29 | 0.510 |
Why?
|
| Protozoan Proteins | 1 | 2016 | 47 | 0.510 |
Why?
|
| Polymorphism, Genetic | 6 | 2011 | 163 | 0.500 |
Why?
|
| Sequence Analysis, DNA | 7 | 2019 | 364 | 0.490 |
Why?
|
| Dendritic Cells | 7 | 2019 | 142 | 0.480 |
Why?
|
| HIV Infections | 6 | 2015 | 146 | 0.480 |
Why?
|
| Monocytes | 1 | 2016 | 132 | 0.480 |
Why?
|
| Lymphocyte Activation | 5 | 2024 | 204 | 0.470 |
Why?
|
| Macaca mulatta | 6 | 2012 | 47 | 0.460 |
Why?
|
| HLA-DRB1 Chains | 2 | 2013 | 33 | 0.460 |
Why?
|
| Immunoglobulin Isotypes | 1 | 2013 | 4 | 0.460 |
Why?
|
| Isoantigens | 1 | 2013 | 4 | 0.460 |
Why?
|
| Graft Rejection | 1 | 2013 | 33 | 0.450 |
Why?
|
| Kidney Transplantation | 2 | 2013 | 43 | 0.450 |
Why?
|
| HLA-DR Antigens | 3 | 2023 | 29 | 0.440 |
Why?
|
| Biomarkers, Tumor | 1 | 2015 | 376 | 0.420 |
Why?
|
| Viral Core Proteins | 2 | 2009 | 8 | 0.420 |
Why?
|
| Antigens, Viral | 2 | 2009 | 23 | 0.400 |
Why?
|
| Female | 19 | 2022 | 14452 | 0.400 |
Why?
|
| Protein Conformation | 6 | 2017 | 250 | 0.380 |
Why?
|
| T-Lymphocytes, Cytotoxic | 6 | 2017 | 30 | 0.380 |
Why?
|
| Oligopeptides | 3 | 2005 | 95 | 0.380 |
Why?
|
| Disease Models, Animal | 5 | 2019 | 1393 | 0.380 |
Why?
|
| RNA-Binding Proteins | 2 | 2009 | 82 | 0.380 |
Why?
|
| T-Lymphocyte Subsets | 2 | 2019 | 56 | 0.380 |
Why?
|
| Base Sequence | 9 | 2019 | 573 | 0.370 |
Why?
|
| Models, Immunological | 3 | 2012 | 22 | 0.370 |
Why?
|
| Chromatography, High Pressure Liquid | 6 | 2013 | 128 | 0.360 |
Why?
|
| Antigens, CD1d | 2 | 2009 | 45 | 0.350 |
Why?
|
| Mammary Neoplasms, Experimental | 2 | 2022 | 48 | 0.340 |
Why?
|
| Ovarian Neoplasms | 1 | 2015 | 563 | 0.340 |
Why?
|
| Binding Sites | 5 | 2018 | 338 | 0.330 |
Why?
|
| Immune Tolerance | 1 | 2009 | 49 | 0.330 |
Why?
|
| Orthomyxoviridae | 1 | 2009 | 4 | 0.330 |
Why?
|
| Mutation, Missense | 1 | 2009 | 67 | 0.330 |
Why?
|
| Molecular Mimicry | 4 | 2017 | 30 | 0.320 |
Why?
|
| Influenza, Human | 1 | 2010 | 84 | 0.320 |
Why?
|
| Allergens | 2 | 2019 | 10 | 0.320 |
Why?
|
| Papio | 2 | 2001 | 78 | 0.310 |
Why?
|
| Simian Immunodeficiency Virus | 4 | 2011 | 5 | 0.310 |
Why?
|
| Lipids | 1 | 2009 | 195 | 0.300 |
Why?
|
| Proteomics | 3 | 2018 | 177 | 0.300 |
Why?
|
| Histocompatibility Antigens Class II | 3 | 2022 | 58 | 0.290 |
Why?
|
| Models, Molecular | 6 | 2016 | 441 | 0.290 |
Why?
|
| HIV | 2 | 2005 | 11 | 0.280 |
Why?
|
| Fluorescence Polarization Immunoassay | 1 | 2006 | 1 | 0.270 |
Why?
|
| Virus Diseases | 1 | 2006 | 38 | 0.270 |
Why?
|
| Amino Acid Substitution | 4 | 2019 | 102 | 0.270 |
Why?
|
| Chromatography, Liquid | 2 | 2018 | 73 | 0.270 |
Why?
|
| Lung | 2 | 2019 | 349 | 0.260 |
Why?
|
| Databases, Protein | 2 | 2022 | 22 | 0.260 |
Why?
|
| Melanoma | 2 | 2019 | 140 | 0.260 |
Why?
|
| Conserved Sequence | 4 | 2011 | 54 | 0.250 |
Why?
|
| Heat-Shock Proteins | 2 | 2005 | 38 | 0.250 |
Why?
|
| Molecular Chaperones | 2 | 2002 | 49 | 0.250 |
Why?
|
| Receptors, Antigen, T-Cell, alpha-beta | 3 | 2019 | 20 | 0.250 |
Why?
|
| Interferons | 2 | 2022 | 68 | 0.250 |
Why?
|
| Fluorescence Polarization | 1 | 2004 | 8 | 0.240 |
Why?
|
| Inuits | 2 | 2002 | 9 | 0.240 |
Why?
|
| Chromatography, Affinity | 2 | 2015 | 32 | 0.240 |
Why?
|
| Flow Cytometry | 6 | 2013 | 282 | 0.230 |
Why?
|
| Ribitol | 1 | 2024 | 1 | 0.230 |
Why?
|
| Uracil | 1 | 2024 | 10 | 0.230 |
Why?
|
| HeLa Cells | 4 | 2017 | 206 | 0.230 |
Why?
|
| Stress, Physiological | 1 | 2004 | 90 | 0.220 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 2 | 2022 | 11 | 0.220 |
Why?
|
| Mutation | 6 | 2017 | 819 | 0.220 |
Why?
|
| Cross Reactions | 5 | 2004 | 65 | 0.210 |
Why?
|
| Melanoma, Experimental | 1 | 2022 | 29 | 0.210 |
Why?
|
| Species Specificity | 4 | 2017 | 186 | 0.210 |
Why?
|
| Haplotypes | 5 | 2018 | 279 | 0.200 |
Why?
|
| Kinetics | 4 | 2011 | 538 | 0.200 |
Why?
|
| B-Lymphocytes | 2 | 2022 | 275 | 0.200 |
Why?
|
| Gene Expression Regulation | 3 | 2019 | 627 | 0.200 |
Why?
|
| ErbB Receptors | 1 | 2022 | 96 | 0.190 |
Why?
|
| Male | 13 | 2019 | 12866 | 0.190 |
Why?
|
| Floxacillin | 1 | 2021 | 1 | 0.190 |
Why?
|
| Haptens | 1 | 2021 | 8 | 0.190 |
Why?
|
| Cancer Vaccines | 3 | 2019 | 32 | 0.190 |
Why?
|
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 3 | 2013 | 54 | 0.180 |
Why?
|
| Phylogeny | 3 | 2001 | 461 | 0.180 |
Why?
|
| H-2 Antigens | 2 | 2018 | 14 | 0.180 |
Why?
|
| Polymorphism, Single Nucleotide | 2 | 2019 | 542 | 0.180 |
Why?
|
| Killer Cells, Natural | 2 | 2017 | 61 | 0.180 |
Why?
|
| Twins, Monozygotic | 1 | 2019 | 6 | 0.170 |
Why?
|
| Lymphocytic choriomeningitis virus | 1 | 2019 | 6 | 0.170 |
Why?
|
| HLA-B15 Antigen | 4 | 2002 | 4 | 0.170 |
Why?
|
| Mice, Inbred Strains | 1 | 2019 | 61 | 0.170 |
Why?
|
| Recombinant Proteins | 3 | 2005 | 408 | 0.170 |
Why?
|
| Sequence Analysis, Protein | 4 | 2011 | 15 | 0.170 |
Why?
|
| Amino Acid Motifs | 4 | 2017 | 66 | 0.170 |
Why?
|
| Adult | 8 | 2019 | 7378 | 0.170 |
Why?
|
| Vaccines, DNA | 2 | 2010 | 11 | 0.170 |
Why?
|
| Blattellidae | 1 | 2019 | 1 | 0.160 |
Why?
|
| Tissue Extracts | 1 | 2019 | 7 | 0.160 |
Why?
|
| Solubility | 3 | 2017 | 73 | 0.160 |
Why?
|
| Zika Virus Infection | 1 | 2019 | 28 | 0.160 |
Why?
|
| Hypersensitivity | 1 | 2019 | 8 | 0.160 |
Why?
|
| Neoplasm Metastasis | 1 | 2019 | 151 | 0.160 |
Why?
|
| Middle Aged | 6 | 2019 | 6812 | 0.160 |
Why?
|
| Coronavirus Infections | 1 | 2019 | 47 | 0.160 |
Why?
|
| Mucosal-Associated Invariant T Cells | 1 | 2018 | 3 | 0.160 |
Why?
|
| Antibody Affinity | 2 | 2015 | 12 | 0.160 |
Why?
|
| Rhinitis, Allergic | 1 | 2018 | 1 | 0.160 |
Why?
|
| Major Histocompatibility Complex | 3 | 2022 | 27 | 0.150 |
Why?
|
| Mammary Neoplasms, Animal | 1 | 2018 | 21 | 0.150 |
Why?
|
| Cell Membrane | 4 | 2009 | 235 | 0.150 |
Why?
|
| Bacterial Infections | 1 | 2018 | 54 | 0.150 |
Why?
|
| Tuberculosis | 1 | 2017 | 23 | 0.150 |
Why?
|
| Virus Replication | 3 | 2019 | 55 | 0.150 |
Why?
|
| Transfection | 4 | 2003 | 312 | 0.150 |
Why?
|
| alpha-Synuclein | 1 | 2017 | 4 | 0.150 |
Why?
|
| Receptors, Natural Killer Cell | 1 | 2017 | 4 | 0.150 |
Why?
|
| Mycobacterium tuberculosis | 1 | 2017 | 28 | 0.150 |
Why?
|
| Receptors, KIR2DL3 | 1 | 2017 | 1 | 0.150 |
Why?
|
| Codon | 1 | 1997 | 22 | 0.150 |
Why?
|
| Primates | 1 | 1997 | 22 | 0.140 |
Why?
|
| Blotting, Western | 4 | 2013 | 503 | 0.140 |
Why?
|
| Host-Pathogen Interactions | 2 | 2015 | 89 | 0.140 |
Why?
|
| Asthma | 1 | 2018 | 57 | 0.140 |
Why?
|
| Vaccines, Synthetic | 1 | 1997 | 8 | 0.140 |
Why?
|
| Parkinson Disease | 1 | 2017 | 39 | 0.140 |
Why?
|
| Interferon-gamma | 5 | 2011 | 102 | 0.140 |
Why?
|
| Cells, Cultured | 4 | 2013 | 970 | 0.140 |
Why?
|
| Cell Line, Transformed | 4 | 2005 | 42 | 0.140 |
Why?
|
| Aged | 4 | 2017 | 5158 | 0.140 |
Why?
|
| Evolution, Molecular | 2 | 2012 | 80 | 0.130 |
Why?
|
| Disease Progression | 2 | 2015 | 450 | 0.130 |
Why?
|
| Transplantation, Heterologous | 1 | 1996 | 60 | 0.130 |
Why?
|
| Antigens, Protozoan | 1 | 2016 | 8 | 0.130 |
Why?
|
| Young Adult | 2 | 2013 | 2578 | 0.130 |
Why?
|
| Mice, Transgenic | 3 | 2021 | 487 | 0.130 |
Why?
|
| Chlamydia trachomatis | 1 | 2015 | 16 | 0.130 |
Why?
|
| Pancreatic Neoplasms | 1 | 2022 | 507 | 0.130 |
Why?
|
| Spectrometry, Fluorescence | 2 | 2006 | 63 | 0.130 |
Why?
|
| MicroRNAs | 1 | 2019 | 280 | 0.130 |
Why?
|
| Phosphopeptides | 1 | 2015 | 11 | 0.130 |
Why?
|
| Mice, Inbred BALB C | 1 | 2016 | 264 | 0.130 |
Why?
|
| Fluorescein-5-isothiocyanate | 2 | 2005 | 17 | 0.130 |
Why?
|
| Immunotherapy, Active | 1 | 2015 | 6 | 0.130 |
Why?
|
| Receptors, KIR | 1 | 2015 | 3 | 0.130 |
Why?
|
| Autoimmunity | 2 | 2017 | 153 | 0.120 |
Why?
|
| gag Gene Products, Human Immunodeficiency Virus | 2 | 2011 | 7 | 0.120 |
Why?
|
| HLA-B35 Antigen | 1 | 2014 | 1 | 0.120 |
Why?
|
| Gene Frequency | 5 | 2015 | 182 | 0.120 |
Why?
|
| DNA Primers | 2 | 2008 | 143 | 0.120 |
Why?
|
| Cytoplasm | 2 | 2005 | 57 | 0.120 |
Why?
|
| Genetic Variation | 3 | 2010 | 229 | 0.120 |
Why?
|
| Polymerase Chain Reaction | 3 | 2001 | 262 | 0.120 |
Why?
|
| Herpesvirus 7, Human | 1 | 2014 | 1 | 0.120 |
Why?
|
| Roseolovirus Infections | 1 | 2014 | 1 | 0.120 |
Why?
|
| Models, Genetic | 4 | 2019 | 123 | 0.120 |
Why?
|
| Antibody-Dependent Cell Cytotoxicity | 1 | 2013 | 7 | 0.110 |
Why?
|
| Immunologic Tests | 1 | 2013 | 3 | 0.110 |
Why?
|
| Transplantation | 1 | 2013 | 2 | 0.110 |
Why?
|
| Carrier Proteins | 2 | 2014 | 245 | 0.110 |
Why?
|
| Leukocytes, Mononuclear | 2 | 2019 | 73 | 0.110 |
Why?
|
| Complement System Proteins | 1 | 2013 | 24 | 0.110 |
Why?
|
| Transgenes | 1 | 2013 | 59 | 0.110 |
Why?
|
| Skin Neoplasms | 1 | 2015 | 128 | 0.110 |
Why?
|
| Tissue Donors | 2 | 2019 | 23 | 0.110 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2013 | 129 | 0.110 |
Why?
|
| Acetylglucosamine | 2 | 2022 | 15 | 0.100 |
Why?
|
| Sequence Analysis | 2 | 2005 | 14 | 0.100 |
Why?
|
| Self Tolerance | 1 | 2012 | 9 | 0.100 |
Why?
|
| Dideoxynucleosides | 1 | 2012 | 12 | 0.100 |
Why?
|
| Anti-HIV Agents | 1 | 2012 | 17 | 0.100 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 2012 | 22 | 0.100 |
Why?
|
| Drug Hypersensitivity | 1 | 2012 | 22 | 0.100 |
Why?
|
| Viral Load | 4 | 2015 | 31 | 0.100 |
Why?
|
| Cytokines | 4 | 2019 | 439 | 0.100 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2015 | 664 | 0.100 |
Why?
|
| Peptide Mapping | 2 | 2003 | 22 | 0.100 |
Why?
|
| Simian Acquired Immunodeficiency Syndrome | 1 | 2011 | 2 | 0.100 |
Why?
|
| DNA, Complementary | 2 | 2001 | 76 | 0.090 |
Why?
|
| Genes, Overlapping | 1 | 2011 | 1 | 0.090 |
Why?
|
| Leukocytes | 1 | 2011 | 67 | 0.090 |
Why?
|
| Cytotoxicity, Immunologic | 3 | 2017 | 26 | 0.090 |
Why?
|
| Antigens | 2 | 2024 | 66 | 0.090 |
Why?
|
| Flavivirus | 1 | 2010 | 1 | 0.090 |
Why?
|
| DNA | 2 | 2005 | 365 | 0.090 |
Why?
|
| West Nile Virus Vaccines | 1 | 2010 | 2 | 0.090 |
Why?
|
| Vaccines, Subunit | 1 | 2010 | 6 | 0.090 |
Why?
|
| Genotype | 3 | 2004 | 441 | 0.090 |
Why?
|
| Hepacivirus | 1 | 2010 | 46 | 0.090 |
Why?
|
| Lysophosphatidylcholines | 1 | 2009 | 4 | 0.090 |
Why?
|
| Peru | 3 | 2015 | 30 | 0.090 |
Why?
|
| Nucleocapsid Proteins | 1 | 2009 | 2 | 0.080 |
Why?
|
| Cross-Priming | 1 | 2009 | 5 | 0.080 |
Why?
|
| Influenza A Virus, H3N2 Subtype | 1 | 2009 | 11 | 0.080 |
Why?
|
| Sequence Homology, Amino Acid | 2 | 2009 | 130 | 0.080 |
Why?
|
| Sphingolipids | 1 | 2009 | 20 | 0.080 |
Why?
|
| Glycerophospholipids | 1 | 2009 | 14 | 0.080 |
Why?
|
| Biomedical Research | 1 | 2010 | 93 | 0.080 |
Why?
|
| HLA-B7 Antigen | 1 | 2009 | 1 | 0.080 |
Why?
|
| Nucleoproteins | 1 | 2009 | 7 | 0.080 |
Why?
|
| Amyloid beta-Protein Precursor | 1 | 2009 | 30 | 0.080 |
Why?
|
| Dogs | 1 | 2010 | 504 | 0.080 |
Why?
|
| Influenza A Virus, H1N1 Subtype | 1 | 2009 | 42 | 0.080 |
Why?
|
| Natural Killer T-Cells | 1 | 2009 | 54 | 0.080 |
Why?
|
| Immunoglobulin E | 2 | 2019 | 18 | 0.080 |
Why?
|
| Signal Transduction | 2 | 2012 | 1344 | 0.080 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2009 | 253 | 0.080 |
Why?
|
| Cyclin-Dependent Kinase 2 | 1 | 2008 | 7 | 0.080 |
Why?
|
| Ornithine Decarboxylase | 1 | 2008 | 8 | 0.080 |
Why?
|
| Sequence Homology | 1 | 2008 | 9 | 0.080 |
Why?
|
| Vero Cells | 1 | 2008 | 12 | 0.080 |
Why?
|
| In Vitro Techniques | 2 | 2005 | 239 | 0.080 |
Why?
|
| Exoribonucleases | 1 | 2008 | 20 | 0.080 |
Why?
|
| Cloning, Molecular | 3 | 2011 | 205 | 0.080 |
Why?
|
| Cytoskeletal Proteins | 1 | 2008 | 42 | 0.080 |
Why?
|
| Antiporters | 2 | 2005 | 6 | 0.070 |
Why?
|
| Nerve Tissue Proteins | 1 | 2009 | 151 | 0.070 |
Why?
|
| Computer Simulation | 3 | 2017 | 221 | 0.070 |
Why?
|
| Tumor Cells, Cultured | 2 | 2009 | 310 | 0.070 |
Why?
|
| Eukaryotic Initiation Factor-4G | 1 | 2006 | 1 | 0.070 |
Why?
|
| Antigen-Antibody Reactions | 1 | 2006 | 12 | 0.070 |
Why?
|
| HLA-DQ Antigens | 2 | 2023 | 25 | 0.070 |
Why?
|
| Binding, Competitive | 1 | 2006 | 62 | 0.070 |
Why?
|
| Monitoring, Immunologic | 2 | 2017 | 7 | 0.070 |
Why?
|
| Structure-Activity Relationship | 3 | 2005 | 200 | 0.070 |
Why?
|
| Titrimetry | 1 | 2006 | 6 | 0.070 |
Why?
|
| Bone Marrow Transplantation | 1 | 2006 | 41 | 0.070 |
Why?
|
| Immunologic Techniques | 1 | 2006 | 12 | 0.070 |
Why?
|
| Homozygote | 2 | 2003 | 36 | 0.070 |
Why?
|
| Nuclear Proteins | 1 | 2008 | 245 | 0.070 |
Why?
|
| Rheumatic Heart Disease | 1 | 2005 | 4 | 0.070 |
Why?
|
| Databases, Bibliographic | 1 | 2005 | 10 | 0.060 |
Why?
|
| Database Management Systems | 1 | 2005 | 12 | 0.060 |
Why?
|
| Hepatitis B virus | 1 | 2005 | 16 | 0.060 |
Why?
|
| Immunologic Memory | 2 | 2019 | 58 | 0.060 |
Why?
|
| Antigen-Presenting Cells | 2 | 2019 | 31 | 0.060 |
Why?
|
| Immunity, Cellular | 1 | 2005 | 23 | 0.060 |
Why?
|
| Artificial Intelligence | 1 | 2005 | 43 | 0.060 |
Why?
|
| Cell Communication | 1 | 2005 | 66 | 0.060 |
Why?
|
| Periodicals as Topic | 1 | 2005 | 50 | 0.060 |
Why?
|
| beta 2-Microglobulin | 1 | 2004 | 5 | 0.060 |
Why?
|
| Epithelial Cells | 1 | 2006 | 240 | 0.060 |
Why?
|
| Alaska | 2 | 2002 | 38 | 0.060 |
Why?
|
| Lysine | 1 | 2005 | 69 | 0.060 |
Why?
|
| Models, Statistical | 1 | 2005 | 118 | 0.060 |
Why?
|
| Clone Cells | 2 | 2019 | 20 | 0.060 |
Why?
|
| Phenotype | 3 | 2015 | 665 | 0.060 |
Why?
|
| Protein Processing, Post-Translational | 1 | 2005 | 98 | 0.060 |
Why?
|
| HLA-B18 Antigen | 1 | 2004 | 1 | 0.060 |
Why?
|
| Databases, Factual | 1 | 2005 | 250 | 0.060 |
Why?
|
| Sequence Alignment | 2 | 2012 | 110 | 0.060 |
Why?
|
| Mice, Inbred C57BL | 2 | 2022 | 1476 | 0.060 |
Why?
|
| HLA-DP Antigens | 1 | 2023 | 3 | 0.060 |
Why?
|
| T-Lymphocytes, Helper-Inducer | 2 | 2017 | 34 | 0.060 |
Why?
|
| Spectrometry, Mass, Electrospray Ionization | 1 | 2004 | 71 | 0.060 |
Why?
|
| Interleukin-2 | 1 | 2003 | 33 | 0.050 |
Why?
|
| Cell Nucleus | 1 | 2004 | 135 | 0.050 |
Why?
|
| Heterozygote | 1 | 2003 | 64 | 0.050 |
Why?
|
| Chromosomal Proteins, Non-Histone | 1 | 2004 | 77 | 0.050 |
Why?
|
| HIV Antigens | 1 | 2002 | 3 | 0.050 |
Why?
|
| Software Design | 1 | 2003 | 7 | 0.050 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2003 | 78 | 0.050 |
Why?
|
| Viral Envelope Proteins | 1 | 2002 | 5 | 0.050 |
Why?
|
| Adjuvants, Immunologic | 1 | 2022 | 62 | 0.050 |
Why?
|
| Kidney Neoplasms | 1 | 2003 | 101 | 0.050 |
Why?
|
| Sequence Analysis, RNA | 1 | 2022 | 57 | 0.050 |
Why?
|
| Internet | 1 | 2003 | 121 | 0.050 |
Why?
|
| Cercopithecus | 1 | 2001 | 2 | 0.050 |
Why?
|
| Gene Library | 1 | 2001 | 45 | 0.050 |
Why?
|
| Biotinylation | 1 | 2001 | 19 | 0.050 |
Why?
|
| Exons | 1 | 2001 | 41 | 0.050 |
Why?
|
| Genetic Markers | 1 | 2001 | 92 | 0.050 |
Why?
|
| Viral Vaccines | 2 | 2011 | 11 | 0.050 |
Why?
|
| Tumor Microenvironment | 1 | 2022 | 143 | 0.050 |
Why?
|
| Introns | 1 | 2001 | 41 | 0.050 |
Why?
|
| Cohort Studies | 2 | 2014 | 859 | 0.050 |
Why?
|
| Bioreactors | 1 | 2000 | 35 | 0.050 |
Why?
|
| Spleen | 1 | 2001 | 109 | 0.050 |
Why?
|
| Transcriptome | 1 | 2022 | 199 | 0.040 |
Why?
|
| Genetic Vectors | 1 | 2000 | 107 | 0.040 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2012 | 586 | 0.040 |
Why?
|
| Datasets as Topic | 1 | 2019 | 21 | 0.040 |
Why?
|
| T-Cell Antigen Receptor Specificity | 1 | 2019 | 3 | 0.040 |
Why?
|
| Lymphocytic Choriomeningitis | 1 | 2019 | 6 | 0.040 |
Why?
|
| Tumor Escape | 1 | 2019 | 8 | 0.040 |
Why?
|
| DNA, Neoplasm | 1 | 2019 | 33 | 0.040 |
Why?
|
| Retroperitoneal Neoplasms | 1 | 2019 | 9 | 0.040 |
Why?
|
| Middle East Respiratory Syndrome Coronavirus | 1 | 2019 | 1 | 0.040 |
Why?
|
| Tropism | 1 | 2019 | 8 | 0.040 |
Why?
|
| Mice, SCID | 1 | 2019 | 59 | 0.040 |
Why?
|
| Cytomegalovirus | 1 | 2019 | 21 | 0.040 |
Why?
|
| Mice, Nude | 2 | 2011 | 313 | 0.040 |
Why?
|
| Skin Tests | 1 | 2019 | 2 | 0.040 |
Why?
|
| Indians, North American | 1 | 2004 | 511 | 0.040 |
Why?
|
| Cytosol | 1 | 1999 | 47 | 0.040 |
Why?
|
| Single-Cell Analysis | 1 | 2019 | 47 | 0.040 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2019 | 106 | 0.040 |
Why?
|
| Zika Virus | 1 | 2019 | 28 | 0.040 |
Why?
|
| Antibodies, Viral | 1 | 2019 | 74 | 0.040 |
Why?
|
| Protein Structure, Tertiary | 1 | 1999 | 283 | 0.040 |
Why?
|
| United States | 2 | 2010 | 2031 | 0.040 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2022 | 441 | 0.040 |
Why?
|
| Protein Structure, Secondary | 1 | 1999 | 130 | 0.040 |
Why?
|
| Korea | 1 | 1998 | 7 | 0.040 |
Why?
|
| Consensus Sequence | 1 | 1998 | 17 | 0.040 |
Why?
|
| Vaccination | 1 | 2019 | 167 | 0.040 |
Why?
|
| Immunohistochemistry | 1 | 2019 | 453 | 0.040 |
Why?
|
| A549 Cells | 1 | 2017 | 16 | 0.040 |
Why?
|
| Leukocyte Immunoglobulin-like Receptor B1 | 1 | 2017 | 2 | 0.040 |
Why?
|
| HLA-B13 Antigen | 1 | 1997 | 1 | 0.040 |
Why?
|
| Costs and Cost Analysis | 1 | 1997 | 39 | 0.040 |
Why?
|
| Recombination, Genetic | 1 | 2017 | 61 | 0.040 |
Why?
|
| Receptors, Immunologic | 1 | 2017 | 64 | 0.040 |
Why?
|
| Reproduction | 1 | 1997 | 63 | 0.030 |
Why?
|
| Antigens, CD | 1 | 2017 | 134 | 0.030 |
Why?
|
| HEK293 Cells | 1 | 2017 | 171 | 0.030 |
Why?
|
| Crystallography, X-Ray | 1 | 2017 | 214 | 0.030 |
Why?
|
| Biological Evolution | 1 | 2017 | 95 | 0.030 |
Why?
|
| HLA-G Antigens | 1 | 1996 | 3 | 0.030 |
Why?
|
| Sequence Homology, Nucleic Acid | 1 | 1996 | 47 | 0.030 |
Why?
|
| Graft vs Host Disease | 1 | 1996 | 25 | 0.030 |
Why?
|
| Chlamydia Infections | 1 | 2015 | 17 | 0.030 |
Why?
|
| Lymphocyte Culture Test, Mixed | 1 | 1995 | 2 | 0.030 |
Why?
|
| MCF-7 Cells | 1 | 2015 | 33 | 0.030 |
Why?
|
| Microscopy, Electron | 1 | 2015 | 94 | 0.030 |
Why?
|
| Lung Neoplasms | 1 | 2019 | 340 | 0.030 |
Why?
|
| CD4 Lymphocyte Count | 1 | 2015 | 13 | 0.030 |
Why?
|
| Homosexuality, Male | 1 | 2014 | 15 | 0.030 |
Why?
|
| Models, Biological | 1 | 2017 | 446 | 0.030 |
Why?
|
| CD11c Antigen | 1 | 2014 | 10 | 0.030 |
Why?
|
| Viral Nonstructural Proteins | 1 | 2014 | 10 | 0.030 |
Why?
|
| CD11b Antigen | 1 | 2014 | 42 | 0.030 |
Why?
|
| Anti-Bacterial Agents | 1 | 2018 | 496 | 0.030 |
Why?
|
| Protein Multimerization | 1 | 2014 | 53 | 0.030 |
Why?
|
| Pregnancy | 1 | 2017 | 1128 | 0.030 |
Why?
|
| Linkage Disequilibrium | 2 | 2004 | 107 | 0.030 |
Why?
|
| Membrane Transport Proteins | 2 | 2005 | 65 | 0.030 |
Why?
|
| Sample Size | 1 | 2012 | 17 | 0.030 |
Why?
|
| Spectrum Analysis | 1 | 2012 | 29 | 0.030 |
Why?
|
| Histocompatibility Antigen H-2D | 1 | 2012 | 6 | 0.030 |
Why?
|
| Aged, 80 and over | 1 | 2017 | 1924 | 0.030 |
Why?
|
| Aging | 1 | 2019 | 943 | 0.030 |
Why?
|
| Genetic Heterogeneity | 1 | 2011 | 30 | 0.020 |
Why?
|
| Thailand | 1 | 2011 | 11 | 0.020 |
Why?
|
| Case-Control Studies | 2 | 2005 | 702 | 0.020 |
Why?
|
| Macaca | 1 | 2011 | 19 | 0.020 |
Why?
|
| Bacterial Proteins | 1 | 2015 | 474 | 0.020 |
Why?
|
| Cross-Sectional Studies | 1 | 2015 | 909 | 0.020 |
Why?
|
| Carcinoma, Ductal, Breast | 1 | 2011 | 15 | 0.020 |
Why?
|
| CD57 Antigens | 1 | 2010 | 3 | 0.020 |
Why?
|
| Tumor Necrosis Factor Receptor Superfamily, Member 7 | 1 | 2010 | 4 | 0.020 |
Why?
|
| Pan troglodytes | 1 | 2011 | 12 | 0.020 |
Why?
|
| Receptors, CCR7 | 1 | 2010 | 4 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2011 | 298 | 0.020 |
Why?
|
| Leukocyte Common Antigens | 1 | 2010 | 17 | 0.020 |
Why?
|
| RNA, Viral | 1 | 2011 | 67 | 0.020 |
Why?
|
| Flavivirus Infections | 1 | 2010 | 1 | 0.020 |
Why?
|
| National Institute of Allergy and Infectious Diseases (U.S.) | 1 | 2010 | 2 | 0.020 |
Why?
|
| Epitopes, B-Lymphocyte | 1 | 2010 | 24 | 0.020 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2011 | 251 | 0.020 |
Why?
|
| Immune System | 1 | 2010 | 29 | 0.020 |
Why?
|
| Phosphorylcholine | 1 | 2009 | 11 | 0.020 |
Why?
|
| Sphingosine | 1 | 2009 | 22 | 0.020 |
Why?
|
| Fluorescent Dyes | 1 | 2010 | 88 | 0.020 |
Why?
|
| Immunoenzyme Techniques | 1 | 2009 | 65 | 0.020 |
Why?
|
| Surface Plasmon Resonance | 1 | 2009 | 37 | 0.020 |
Why?
|
| DNA-Directed DNA Polymerase | 1 | 2009 | 4 | 0.020 |
Why?
|
| Cell Survival | 1 | 2011 | 394 | 0.020 |
Why?
|
| Transcription, Genetic | 1 | 2011 | 400 | 0.020 |
Why?
|
| DEAD-box RNA Helicases | 1 | 2009 | 26 | 0.020 |
Why?
|
| Peptide Library | 1 | 2009 | 25 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2010 | 324 | 0.020 |
Why?
|
| Survival Analysis | 1 | 2010 | 276 | 0.020 |
Why?
|
| Breast | 1 | 2009 | 51 | 0.020 |
Why?
|
| HLA-A24 Antigen | 1 | 2009 | 1 | 0.020 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2009 | 110 | 0.020 |
Why?
|
| Immunoprecipitation | 1 | 2009 | 67 | 0.020 |
Why?
|
| Prognosis | 1 | 2011 | 759 | 0.020 |
Why?
|
| Age Factors | 1 | 2010 | 716 | 0.020 |
Why?
|
| Apoptosis | 1 | 2011 | 739 | 0.020 |
Why?
|
| HLA-D Antigens | 1 | 2006 | 6 | 0.020 |
Why?
|
| Receptor, ErbB-2 | 1 | 2006 | 32 | 0.020 |
Why?
|
| Cardiac Myosins | 1 | 2005 | 12 | 0.020 |
Why?
|
| Markov Chains | 1 | 2005 | 16 | 0.020 |
Why?
|
| Th1 Cells | 1 | 2005 | 35 | 0.020 |
Why?
|
| Natural Language Processing | 1 | 2005 | 16 | 0.020 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2006 | 243 | 0.020 |
Why?
|
| Pattern Recognition, Automated | 1 | 2005 | 32 | 0.020 |
Why?
|
| Antimetabolites | 1 | 2005 | 5 | 0.020 |
Why?
|
| Inflammation | 1 | 2009 | 601 | 0.020 |
Why?
|
| HLA-B8 Antigen | 1 | 2005 | 1 | 0.020 |
Why?
|
| Isomerases | 1 | 2005 | 2 | 0.020 |
Why?
|
| Protein Disulfide-Isomerases | 1 | 2005 | 6 | 0.020 |
Why?
|
| Protein Folding | 1 | 2005 | 47 | 0.020 |
Why?
|
| ATP-Binding Cassette Transporters | 1 | 2005 | 35 | 0.020 |
Why?
|
| Alanine | 1 | 2005 | 40 | 0.020 |
Why?
|
| Tryptophan | 1 | 2005 | 39 | 0.020 |
Why?
|
| Bacterial Outer Membrane Proteins | 1 | 2005 | 94 | 0.020 |
Why?
|
| Endoplasmic Reticulum | 1 | 2005 | 77 | 0.010 |
Why?
|
| Protein Transport | 1 | 2005 | 152 | 0.010 |
Why?
|
| Histocompatibility | 1 | 2004 | 4 | 0.010 |
Why?
|
| Antigens, Bacterial | 1 | 2005 | 159 | 0.010 |
Why?
|
| South Dakota | 1 | 2004 | 20 | 0.010 |
Why?
|
| Genes, MHC Class II | 1 | 2004 | 10 | 0.010 |
Why?
|
| Likelihood Functions | 1 | 2004 | 26 | 0.010 |
Why?
|
| Up-Regulation | 1 | 2005 | 240 | 0.010 |
Why?
|
| Kidney Failure, Chronic | 1 | 2004 | 68 | 0.010 |
Why?
|
| AIDS Vaccines | 1 | 2002 | 2 | 0.010 |
Why?
|
| CD40 Ligand | 1 | 2002 | 13 | 0.010 |
Why?
|
| Phosphatidylethanolamines | 1 | 2002 | 23 | 0.010 |
Why?
|
| HLA-DQ beta-Chains | 1 | 2002 | 14 | 0.010 |
Why?
|
| Herpesvirus 8, Human | 1 | 2002 | 12 | 0.010 |
Why?
|
| Immunophenotyping | 1 | 2002 | 58 | 0.010 |
Why?
|
| Survival Rate | 1 | 2003 | 406 | 0.010 |
Why?
|
| Glutamine | 1 | 2002 | 32 | 0.010 |
Why?
|
| Aspartic Acid | 1 | 2002 | 52 | 0.010 |
Why?
|
| Histidine | 1 | 2002 | 50 | 0.010 |
Why?
|
| Liposomes | 1 | 2002 | 142 | 0.010 |
Why?
|
| Substrate Specificity | 1 | 2002 | 149 | 0.010 |
Why?
|
| Retrospective Studies | 1 | 2006 | 2427 | 0.010 |
Why?
|
| Treatment Outcome | 1 | 2003 | 2262 | 0.010 |
Why?
|